World J Mens Health.  2012 Aug;30(2):93-98.

Therapeutic Angiogenesis as a Potential Future Treatment Strategy for Erectile Dysfunction

• Ryu JK
• Suh JK

Abstract

The cavernous endothelium plays a crucial role in regulating the tone of the underlying smooth muscle and physiologic penile erection. Recently, the link between erectile dysfunction (ED) and cardiovascular disease was unveiled, and the main etiology of ED was found to be vasculogenic. Although oral phosphodiesterase-5 inhibitors are generally effective for men with ED, such therapies do not cure underlying vasculopathy in the corpus cavernosum tissue. This review addresses current preclinical protein, gene, and cell or stem cell therapies for enhancing cavernous endothelial regeneration and restoring erectile function.

Keyword

Erectile dysfunction; Endothelium; Angiogenesis inducing agents

MeSH Terms

Aluminum Hydroxide
Angiogenesis Inducing Agents
Carbonates
Cardiovascular Diseases
Caves
Cyclic Nucleotide Phosphodiesterases, Type 5
Endothelium
Erectile Dysfunction
Humans
Male
Muscle, Smooth
Penile Erection
Regeneration
Stem Cells
Aluminum Hydroxide
Angiogenesis Inducing Agents
Carbonates
Cyclic Nucleotide Phosphodiesterases, Type 5

Reference

1. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003. 108:2054–2059.

2. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl. 2003. 24:6 Suppl. S17–S37.

3. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int. 2001. 87:838–845.

4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994. 151:54–61.

5. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998. 338:1397–1340.

6. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001. 13:192–199.

7. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002. 168:1332–1336.

8. Ryu JK, Shin HY, Song SU, Oh SM, Piao S, Han JY, et al. Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia. Urology. 2006. 67:1329–1334.

9. Azadzoi KM. Vasculogenic erectile dysfunction: beyond the haemodynamic changes. BJU Int. 2006. 97:11–16.

10. Wang T, Soker S, Atala A, Siroky MB, Azadzoi KM. Alterations in angiogenic growth factors and neuronal nitric oxide synthase expression in chronic cavernosal ischemia. Int J Impot Res. 2004. 16:403–411.

11. Tomada N, Tomada I, Cruz F, Vendeira P, Neves D. Characterization of VEGF and angiopoietins expression in human corpus cavernosum during aging. J Sex Med. 2010. 7:1410–1418.

12. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res. 2003. 15:26–37.

13. Dall'Era JE, Meacham RB, Mills JN, Koul S, Carlsen SN, Myers JB, et al. Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model. Int J Impot Res. 2008. 20:307–314.

14. Gholami SS, Rogers R, Chang J, Ho HC, Grazziottin T, Lin CS, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol. 2003. 169:1577–1581.

15. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura A, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol. 2005. 173:318–323.

16. Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M, et al. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther. 2006. 13:705–715.

17. Jin HR, Kim WJ, Song JS, Piao S, Choi MJ, Tumurbaatar M, et al. Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. Diabetes. 2011. 60:969–980.

18. Jin HR, Kim WJ, Song JS, Piao S, Tumurbaatar M, Shin SH, et al. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. J Sex Med. 2010. 7:3635–3646.

19. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998. 97:1114–1123.

20. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. 1998. 2:549–558.

21. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000. 102:898–901.

22. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996. 87:1161–1169.

23. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995. 376:70–74.

24. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999. 286:2511–2514.

25. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol. 2000. 20:2573–2578.

26. Jones MK, Kawanaka H, Baatar D, Szabó IL, Tsugawa K, Pai R, et al. Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. Gastroenterology. 2001. 121:1040–1047.

27. Harraz A, Shindel AW, Lue TF. Emerging gene and stem cell therapies for the treatment of erectile dysfunction. Nat Rev Urol. 2010. 7:143–152.

28. Temin HM. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther. 1990. 1:111–123.

29. Kabanov AV, Kabanov VA. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjug Chem. 1995. 6:7–20.

30. Lee M, Ryu JK, Piao S, Choi MJ, Kim HA, Zhang LW, et al. Efficient gene expression system using the RTP801 promoter in the corpus cavernosum of high-cholesterol diet-induced erectile dysfunction rats for gene therapy. J Sex Med. 2008. 5:1355–1364.

31. Azadzoi KM, Park K, Andry C, Goldstein I, Siroky MB. Relationship between cavernosal ischemia and corporal veno-occlusive dysfunction in an animal model. J Urol. 1997. 157:1011–1017.

32. Ryu JK, Lee M, Choi MJ, Kim HA, Jin HR, Kim WJ, et al. Gene therapy with an erythropoietin enhancer-mediated hypoxia-inducible gene expression system in the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. J Androl. 2012. [Epub ahead of print].

33. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000. 2:302–317.

34. Demeneix B, Behr JP. Polyethylenimine (PEI). Adv Genet. 2005. 53:217–230.

35. Wong SY, Pelet JM, Putnam D. Polymer systems for gene delivery-past, present, and future. Prog Polym Sci. 2007. 32:799–837.

36. Lee M, Ryu JK, Oh SM, Lee E, Shin HY, Song SU, et al. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res. 2005. 17:326–334.

37. Garcia MM, Fandel TM, Lin G, Shindel AW, Banie L, Lin CS, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med. 2010. 7:89–98.

38. Huang YC, Ning H, Shindel AW, Fandel TM, Lin G, Harraz AM, et al. The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. J Sex Med. 2010. 7:1391–1400.

39. Qiu X, Lin H, Wang Y, Yu W, Chen Y, Wang R, et al. Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. J Sex Med. 2011. 8:427–436.

40. Ryu JK, Tumurbaatar M, Jin HR, Kim WJ, Kwon MH, Choi MJ, et al. Intracavernous delivery of freshly isolated adipose tissue-derived stromal vascular fraction rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. J Sex Med. 2012. [In press].

41. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001. 7:211–228.

42. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells. 2006. 24:376–385.

43. Miranville A, Heeschen C, Sengenès C, Curat CA, Busse R, Bouloumié A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation. 2004. 110:349–355.

44. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004. 109:1292–1298.